Truist Financial Raises the PT on Pediatrix Medical (MD), Keeps a Buy

​Pediatrix Medical Group, Inc. (NYSE:MD) is one of the Hottest Small Cap Stocks to Buy Now. On November 10, David S Macdonald from Truist Financial raised the firm’s price target on Pediatrix Medical Group, Inc. (NYSE:MD) from $17 to $24, while reiterating a Buy rating.

​The enhanced positive outlook follows a 33.59% increase in share price since the company released its fiscal Q3 2025 results on November 3. The company delivered $492.88 million in quarterly revenue, down 3.58% year-over-year, but surpassing analysts’ estimates by $16.43 million. The EPS of $0.67 also topped the consensus by $0.20.

​Management attributed the decrease in revenue to its portfolio restructuring activity of approximately $54 million. However, the decrease was offset by 8% growth in same-unit, 7.5% increase in same-unit pricing, and around 40 basis points increase in patient service volumes.

​In addition, the adjusted EBITDA for the quarter reached $87 million, exceeding management’s expectations. This was driven by positive pricing outcomes, collections, and expense controls. As a result, Pediatrix Medical Group, Inc. (NYSE:MD) raised its full-year adjusted EBITDA guidance to a range of $270 million to $290 million, up from the previous guidance range of $245 million to $255 million.

​Pediatrix Medical Group, Inc. (NYSE:MD) is a leading provider of specialized physician services for women, babies, and children, focusing on newborn, maternal-fetal, and pediatric subspecialty care.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.